About Team Argonaut

Before joining Telegraph Hill Partners, Alex worked at Genzyme Corporation in the Oncology / Multiple Sclerosis Business Development Group, where he sourced, evaluated, and executed strategic M&A and licensing biopharma transactions. Prior to Genzyme, he worked as a portfolio manager at BlueMountain Capital Management, and as an investment banking analyst at Bank of America Securities.

Deval Lashkari has worked in the life sciences area since 1988 developing and commercializing novel technologies and is a founding partner at Telegraph Hill Partners. He gained corporate and business development experience through senior management positions in a number of life science companies. He was a founding Research Director at Synteni, which was acquired by Incyte Genomics, where he became Director of Product Development. He also worked with Operon Technologies (acquired by Qiagen), and Genometrix.

Before joining Telegraph Hill Partners, Paul Grossman was Head of Strategy and Corporate Development for Life Technologies, holding a similar position at Invitrogen Corporation prior to the merger with Applied Biosystems. Paul has held a variety of leadership and executive roles in R&D, Legal and Corporate Development teams, including spearheading the acquisition or divestment of more than 25 businesses

With 34 years of life sciences experience in senior management, R&D, operations, and quality, Rick was most recently the CEO of Althea Technologies Inc. Prior to Althea Technologies he was the senior director of operations at The Immune Response Corporation. Rick has significant experience in cGMP manufacturing, regulatory affairs, scale up, operational protocols, and team management. He also worked at Hybritech as a quality control analyst, research associate, and laboratory supervisor.